Good clinical practices working group l.jpg
This presentation is the property of its rightful owner.
Sponsored Links
1 / 59

GOOD CLINICAL PRACTICES WORKING GROUP PowerPoint PPT Presentation


  • 118 Views
  • Uploaded on
  • Presentation posted in: General

GOOD CLINICAL PRACTICES WORKING GROUP. Update and Proposal IV Pan American Conference on Drug Regulatory Harmonization República Dominicana 2-4 March, 2005 . Good Clinical Practices WG Members. ARGENTINA: Patricia Saidón, ANMAT, Coordinator (*) BRASIL:

Download Presentation

GOOD CLINICAL PRACTICES WORKING GROUP

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Good clinical practices working group l.jpg

GOOD CLINICAL PRACTICES WORKING GROUP

Update and Proposal

IV Pan American Conference on Drug Regulatory Harmonization

República Dominicana 2-4 March, 2005


Good clinical practices wg members l.jpg

Good Clinical Practices WG Members

  • ARGENTINA:

    Patricia Saidón, ANMAT, Coordinator (*)

  • BRASIL:

    Granville García de Oliveira, ANVISA

    Sergio Nishioka , ANVISA (*)

  • CHILE:

    Beatriz Marincovich, ISP

    Eduardo Johnson, ISP (*)


Good clinical practices wg members3 l.jpg

Good Clinical Practices WG Members

  • COSTA RICA:

    • Guillermo Rodriguez

    • Graciela Salazar

    • Hernán Collado

    • Jorge López

    • Gilda Granados Gavelman , Consejo Nacional de Investigación, Ministerio de Salud (*)

  • CARICOM:

    • Henri Fraser, Prof. University of West Indies, Barbados


Good clinical practices wg members4 l.jpg

Good Clinical Practices WG Members

  • CUBA:

    • María Amparo Pascual, Centro Coordinador de Ensayos Clínicos (CENCEC) (*)

  • MEXICO:

    • Alberto Frati

    • Juan Jesús Sanchez

  • USA:

    • David Lepay

    • Stan Woollen, Food and Drug Administration (*)


Good clinical practices wg members5 l.jpg

Good Clinical Practices WG Members

  • VENEZUELA:

    • María Aguilar, Centro Nacional de Farmacología, Instituto Nacional de Higiene “Rafael Rangel” (*)

  • ALIFAR:

    • José Cortez,

    • Luis Yushimito

    • Manuel Ruiz Caballero (*)


Good clinical practices wg members6 l.jpg

Good Clinical Practices WG Members

  • FIFARMA:

    • León Arango,

    • Silvia Zieher,

    • Noemí Rosa

    • Celso Arabehety(*)

  • SECRETARIAT:

    • Rosario D´Alessio, PAHO

    • Alejandro Midzuaray, PAHO/WHO, Perú

    • Juana Mejía de Rodriguez: PAHO/WHO PWR Guatemala


Background l.jpg

BACKGROUND

  • Until recently, clinical trials were concentrated in developed countries

  • The number of patients enrolled in international multi-centre clinical trials has increased in some countries of our region.

  • In 1993 2.1% of clinical trials were done in Latin America; in 1997, 5.1% and in 2000, 7.5%. (IMS Health)


Background8 l.jpg

BACKGROUND

  • L.A. has been included in early phases of new drug development

  • As a result, there are more sites, investigators, committees, CROs, and research-related staff in pharmaceutical companies


Background9 l.jpg

BACKGROUND

  • 1995: Guidelines for GCP for Trials on Pharmaceutical Products (WHO)

  • ICDRA recommendations (Madrid 2004)

    • Member countries should implement the document

    • Member countries should guarantee the informed consent process

    • Biological Samples in Genetics Studies should follow GCP guidelines

    • Gene Therapy is a new area of medicine requiring rigorous implementation of GCPs and ethics

    • WHO was asked to explore options for providing experts to strengthen the R.A. of countries with limited resources


Background10 l.jpg

BACKGROUND

  • International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)

    • E6: Good Clinical Practices

    • E2a, E2b, E2c, E2ca, E2d, E2e: Clinical safety data Management

    • E3: Structure and content of Clinical Study Report

    • E5: Ethnic Factors in the acceptability of foreign clinical data

    • E7: Geriatrics: General Considerations for Clinical Research

    • E9: Statistical Principles for Clinical Research

    • E10: Choice of Control Groups

    • E11: Clinical Investigation of Medicinal Products for Pediatrics Population


Background11 l.jpg

BACKGROUND

IN LATIN AMERICA

  • Meeting of Experts on GCP (1999, Bs As)

  • II Pan American Conference on Drug Regulatory Harmonization, established the GCP WG (1999)

  • Assessment of GCP situation in the area (2000)

  • Mission and Objectives of the GCP WG were defined


Background12 l.jpg

BACKGROUND

IN AMERICA

  • III Pan American Conference on Drug Regulatory Harmonization (2002): Approved Ethics Committee and Informed Consent documents

  • III Pan American Conference on Drug Regulatory Harmonization (2002) recommended harmonizing procedures for evaluating protocols of clinical trials and developing guidelines for inspections and directives on pediatric investigation


Background13 l.jpg

BACKGROUND

GCP DOCUMENT OF THE AMERICAS

  • Guideline for Regulatory Authorities on the authorization

  • Guideline for Regulatory Authorities on the Inspection

  • Guideline to Investigators, Ethics Committees, Universities and Industry


Good clinical practices document of the americas l.jpg

GOOD CLINICAL PRACTICESDocument of the Americas


Good clinical practices document of the americas15 l.jpg

Introduction

Principles

IEC/IRB

Informed Consent

Investigator Responsibilities

Sponsor Responsibilities

GCP Compliance Monitoring Program by R:A

Protocol

Glossary

ANNEXES

Operational Guidelines for IEC

A Self-Evaluation Questionnaire for IEC´s (Check List)

Operational Guidelines for Informed Consent

A Inspections

Guide to Clinical Investigator

Essential Documents

Good Clinical Practices Document of the Americas


Chapter 1 introduction l.jpg

Chapter 1: Introduction

  • Clinical trial is a systematic study with drugs and/or medicinal specialties in human volunteers that strictly follows the scientific method. Its purpose is to explore and verify the effects and/or the adverse reactions to an investigational product and/or the pharmacokinetics of the active ingredients, in order to determine their efficacy and safety

  • Clinical Trials involving human beings contribute significantly to the improvement of human health


Chapter 1 introduction17 l.jpg

Chapter 1: Introduction

  • Clinical trials are needed to demonstrate the efficacy and safety of the drugs

  • Since the relevance of developing these trials for national and international standards for clinical pharmacological research are necessary.

  • It becomes necessary to establish harmonized criteria for GCP in the Americas


Chapter 2 principles l.jpg

Chapter 2: PRINCIPLES

Clinical trials are conducted aiming and obtaining evidence regarding efficacy and safety of products that, in addition to non-clinical evidence and quality data should support their registration by a regulatory authority. Ethical principles based primarily on the Declaration of Helsinki should be the basis for the approval and conduction of clinical trials. Three basic ethical principles of equal moral force, namely respect for persons, beneficence and justice, permeate all the GCP principles enumerated below


Chapter 2 principles19 l.jpg

Chapter 2: PRINCIPLES

  • Clinical trials should be conducted only if the anticipated benefits for the individual trial subject and society clearly outweigh the risk involved

  • Although the benefit of the results of the clinical trial to science and society are important and should be taken into account, the most important considerations are those related to the rights, safety and well-being of the trial subjects


Chapter 2 principles20 l.jpg

Chapter 2: PRINCIPLES

  • A trial should be conducted in compliance with the protocol that has received prior institutional review board (IRB)/independent ethics committee (IEC) approval/favorable opinion

  • Approval of clinical trials of investigational products should be supported by adequate non-clinical and, when applicable, clinical information


Chapter 2 principles21 l.jpg

Chapter 2: PRINCIPLES

  • Clinical trials should be scientifically sound, and described in a clear, detailed protocol

  • Freely given informed consent should be obtained from every subject prior to clinical trial participation


Chapter 2 principles22 l.jpg

Chapter 2: PRINCIPLES

  • Qualified physicians (or, if appropriate, qualified dentist) should be responsible for the medical care of trial subjects, and for any medical decision made on their behalf

  • These professionals should be adequately qualified by education, training and experience to perform their tasks regarding the trial and trial subjects

  • Recording, handling and storage of all clinical trial information should be appropriate to allow accurate trial reporting, interpretation and verification


Chapter 2 principles23 l.jpg

Chapter 2: PRINCIPLES

  • The confidentiality of records that could identify subjects should be protected respecting the privacy and confidentiality rules in accordance with the applicable regulatory requirements

  • Investigational products should be manufactured, handled, and stored in accordance with applicable good manufacturing practices (GMP), and should be used in accordance with the approved protocol

  • Systems with procedures that assure the quality of every aspect of the trial should be implemented


Chapter 3 investigational ethics committee institutional review board l.jpg

Chapter 3: Investigational Ethics Committee/Institutional Review Board

  • The III Pan American Conference approved the document

  • Investigational Ethics Committee/Institutional Review Board (IEC/IRB)

    • Structure and Responsibilities of the Ethics Committee

    • Composition of the IEC/IRB

    • Functions and operations

    • Procedures

    • Records


Chapter 4 informed consent l.jpg

Chapter 4: INFORMED CONSENT

  • The Document was approved by the III Pan American Conference

  • Informed Consent:

    • Definition

    • Parts of Informed Consent

    • Guidelines for obtaining Informed Consent

    • Elements of Informed Consent


Chapter 5 investigator resposibilities l.jpg

Chapter 5: Investigator Resposibilities

  • Investigator´s Qualifications and Agreements

  • Adequate Resources

  • Medical Care of Trial Subjects

  • Informed Consent- Communication with IRB/IEC

  • Compliance with Protocol

  • Investigational Product


Chapter 5 investigator resposibilities27 l.jpg

Chapter 5: Investigator Resposibilities

  • Randomization Procedures/ Records and Reports

  • Progress Reports/Final Report

  • Safety Reporting

  • Premature Termination or Suspention of a Trial

  • Financial Aspects


Chapter 6 sponsor responsibilities l.jpg

Chapter 6: Sponsor Responsibilities

  • Quality Assurance and Quality Control

  • Contract Research Organization

  • Medical Expertise

  • Trial Design

  • Trial Management, Data Handlling, Recordkeeping and Independent Data Monitoring Committee


Chapter 6 sponsor responsibilities29 l.jpg

Chapter 6: Sponsor Responsibilities

  • Investigator Selection

  • Allocation of Duties and Functions

  • Compensation to Subjects and Investigators

  • Financing

  • Notification/Submission to regulatory Authority(ies)


Chapter 6 sponsor responsibilities30 l.jpg

Chapter 6: Sponsor Responsibilities

  • Confirmation of Review by IEC/IRB

  • Information on Investigational Product(s)

  • Manufacturing, Packaging, Labeling and Coding Investigational Product(s)

  • Supplying and Handling Investigational Product(s)

  • Record Access


Chapter 6 sponsor responsibilities31 l.jpg

Chapter 6: Sponsor Responsibilities

  • Safety Information

  • ADR reports

  • Monitoring

  • Audit

  • Noncompliance

  • Premature Discontinuation and Suspension of a Trial

  • Clinical Trial Reports

  • Multicentre Trials


Gcp compliance monitoring programs by r a l.jpg

GCP Compliance Monitoring Programs by R.A.

  • Objective:The aim of the program is to monitor compliance with GCP through inspections to all parties involved in the clinical trial

  • Purpose of the National GCP Compliance Program: A GCP Compliance Monitoring Program is indented to ascertain whether clinical trials have been conducted in accordance with acceptable GCP standards as necessary to ensure the quality and integrity of study data and the protection of the rights and welfare of research subjects. RA should publish the details of their (National) GCP Compliance Program


Gcp compliance monitoring programs by r a33 l.jpg

GCP Compliance Monitoring Programs by R.A.

Organization/Administration:

  • A (National) GCP Compliance Monitoring Program should be the responsibility of a properly constituted, legally identifiable body adequately staffed and working within a defined administrative framework. It is recommended that such program be under the responsibility of the existing DRA


Gcp compliance monitoring programs by r a34 l.jpg

GCP Compliance Monitoring Programs by R.A.

Personnel and Training:

  • A (National) GCP Compliance Monitoring Authorities should:

    • Ensure that an adequate number of Inspectors are available

    • Ensure that Inspectors are adequately qualified and trained

  • Inspectors should have qualifications and practical expertise in the range of scientific and regulatory disciplines relevant to GCP


Gcp compliance monitoring programs by r a35 l.jpg

GCP Compliance Monitoring Programs by R.A.

Personnel and Training:

  • A (National) GCP Compliance Monitoring Authorities should ensure that inspectorate personnel, including experts under contract, have no financial or other interest in the trial sites or products and studies inspected or the firms sponsoring such studies

  • Inspectors may be on the permanent staff of the GCP Monitoring authority or on the permanent staff of a body separate from GCP Monitoring Authority or employed on contract by the GCP Monitoring Authority to perform inspections ( in the last case the GCP Monitoring Authority has the ultimate responsibility for determining GCP compliance status , the acceptability of the data and for taking actions.


Clinical protocol l.jpg

Clinical Protocol

The Clinical Trial will follow an written Protocol, signed by the sponsor and the investigator

Every amendment should be also signed by both parties


Clinical protocol37 l.jpg

Clinical Protocol

  • General Information

  • Background

  • Objectives

  • Design

  • Selection Criteria

  • Treatment


Clinical protocol38 l.jpg

Clinical Protocol

  • Efficacy Evaluation

  • Safety Evaluation

  • Statistics

  • Direct Access to Data

  • Quality Control and Quality Assurance


Annexes l.jpg

Annexes


Operational guidelines for ethics committees that review biomedical research tdr who 2000 l.jpg

Operational Guidelines for Ethics Committees that Review Biomedical Research (TDR-WHO 2000)

  • These Guidelines are intended to facilitate and support ethical review

  • They are based on a closed examination of the requirements for ethical review as established in international guidelines, as well as on an evaluation of existing practices of ethical review in countries around the world


Surveying and evaluating ethical review practices a complementary guideline tdr who 2002 l.jpg

Surveying and Evaluating Ethical Review Practices: a complementary guideline (TDR- WHO 2002)

  • This guideline is intended to be complementary to the Operational Guidelines

  • Its purpose is to facilitate and support procedures for assisting the development of quality and transparency in ethical review

  • It´s developed as a tool to contribute to the education of IEC through review and evaluation of their practices

  • It´s intended to contribute to justified public trust in the ethical review and to assist public authorities and national associations involved with developing ethical review systems in promoting Good Ethical Practices


A self evaluation questionnaire for iec s check list l.jpg

A Self-Evaluation Questionnaire for IEC´s (CHECK LIST)

This questionnaire may be useful to define procedures of new IEC/IRBs, and for reviewing organization and operation procedures of established IEC/IRBs. Most items listed are applicable also to ethics committees that are not affiliated with a particular institution (Independent). The written procedures can be audited to verify appropriate compliance


Model for basic structure of the informed consent document l.jpg

Model for Basic Structure of the Informed Consent Document

  • The III Pan American Conference on Drug Regulatory Harmonization approved the Document

    • General Information

    • Specific Information

    • Rights of the Subjects

    • Signature Model


Operational guidelines for informed consent l.jpg

Operational Guidelines for Informed Consent

  • The III Pan American Conference on Drug Regulatory Harmonization approved the document

  • This Guideline will be an instrument to:

    • To write an Informed Consent.

    • To obtain the Informed Consent

  • Contents of the document:

    • Language

    • Information to the subjects

    • Signature Form

    • Guidelines for obtaining Informed Consent


Check list of requirements for the informed consent form l.jpg

Check List of Requirements for the Informed Consent Form

  • This Check List may be useful for Investigators, IECs/IRBs , sponsors and R.As to check the elements of the Informed Consent

  • The Document was approved by the III Pan American Conference on Drug Regulatory Harmonization


A guide to clinical investigator inspections l.jpg

A Guide to Clinical Investigator Inspections

This Document provides a guide to inspectors and R.A for planning, conducting and reporting clinical investigator inspections

The objectives of these inspections are to assure the quality and integrity of clinical trial data relied upon by R.A. and to assure that the rights and welfare of research subject are protected


A guide to clinical investigator inspections47 l.jpg

A Guide to Clinical Investigator Inspections

Planning the Inspection

  • Selection of the studies

  • Identification of Inspectors

  • Preparing the Inspection

  • Scheduling the Inspection


A guide to clinical investigator inspections48 l.jpg

A Guide to Clinical Investigator Inspections

Conducting the Inspection

  • Opening Interview

  • Study Records review

    • Records inventory

    • Protocol

    • Subjects’ Records

    • Human subjects protection documentation

    • Drug Accountability

  • Planning the Inspection

  • Scheduling the Inspection


A guide to clinical investigator inspections49 l.jpg

A Guide to Clinical Investigator Inspections

Documenting and Reporting the Inspection

  • Documentation during the Inspection

  • Reporting after the Inspection


Essential documents for clinical trials l.jpg

Essential Documents for Clinical Trials

  • Essential Documents are those documents that individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced

  • The minimum list of Essential Documents are grouped in three sections

    • Before the clinical trial commences

    • During the clinical conduct of the trial

    • After completion of the trial

  • The list of Essential Document are listed in investigator/institution documents and sponsor documents


Propuesta 1 l.jpg

Propuesta (1)

Aprobar las siguiente Misión y Objetivos para el Grupo de trabajo de BPC

Misión:

Promover la armonización de las BPC en las Américas

Objetivos:

  • Promover la implementación de las BPC en las Américas

  • Diseminar el Documento Buenas Prácticas Clínicas: Documento de las Américas recomendando su adopción en las regulaciones nacionales y

  • Desarrollar e implementar programas educativos sobre BPC especialmente dirigidos a AR


Propuesta 2 l.jpg

Propuesta (2)

Adoptar el Documento

Buenas Prácticas Clínicas: Documento de las Américas


Propuesta 3 l.jpg

Propuesta (3)

Solicitar a :

AR

Universidades

Industria Framacéutica

Red PARF y GT BPC

IV Pan American Conference on Drug Regulatory Harmonization 2-4 March 2005


Autoridades nacional regulatoria de medicamentos l.jpg

Autoridades Nacional Regulatoria de Medicamentos

Adoptar e incorporar en su marco regulatorio nacional el DocumentoBuenas Prácticas Clínicas: Documento de las Américas

Promover procesos de capacitación en inspecciones de BPC y en evaluación de estudios clínicos con medicamentos

Promover la adopción del documento Buenas Prácticas Clínicas: Documento de las Américas en los grupos sub-regionales de integración económica

IV Pan American Conference on Drug Regulatory Harmonization 2-4 March 2005


Universidades nacionales l.jpg

Universidades Nacionales

Promover la educación contínua en Buenas Practicas Clínicas para Investigadores, patrocinadores, reguladores y miembros de Comités de Etica

Establecer las bases de esta formación en los programas de pre-grado y en el desarrollo de los cursos de educación contínua

Promover el trabajo conjunto en el establecimiento de programas educativos sobre BPC con la asistencia de todos los sectores interesados

IV Pan American Conference on Drug Regulatory Harmonization 2-4 March 2005


Industria farmac utica y universidades l.jpg

Industria Farmacéutica y Universidades

Que las Investigaciones Clínicas que se desarrollen en la región se adapten a la normativa prevista en el documento: Buenas Prácticas Clínicas: Documento de las Américas

Promover la incorporación del documento Buenas Prácticas Clínicas: Documento de las Américas en los programas de entrenamiento

IV Pan American Conference on Drug Regulatory Harmonization 2-4 March 2005


A la red parf y al gt bpc l.jpg

A la Red PARF y al GT BPC

Incluir en su plan de trabajo el seguimiento acerca del grado de incorporación del documento Buenas Prácticas Clínicas: Documento de las Américas en la práctica regulatoria sobre BPC de los países de la región

Apoyo técnico del GT BPC a países con compromiso de adoptar el documento Buenas Prácticas Clínicas: Documento de las Américas

Promover Inspecciones de BPC conjuntas

IV Pan American Conference on Drug Regulatory Harmonization 2-4 March 2005


A la red parf y al gt bpc58 l.jpg

A la Red PARF y al GT BPC

  • Desarrollar un programa de capacitación en Inspecciones de BPC y en evaluación de estudios clínicos , teniendo presente la expériencia de países que que han acumulado experiencia sobre el tema

  • Que el GT BPC elabore un informe sobre el grado de avance en la adopción del documento Buenas Prácticas Clínicas: Documento de las Américas para ser presentado en la próxima conferencia


Muchas gracias muito obrigada thank you merci l.jpg

Muchas gracias Muito ObrigadaThank youMerci


  • Login